American Journal of Respiratory and Critical Care Medicine

Metformin: Experimental and clinical evidence for a potential role in emphysema treatment.  204:651-666. 2021

Micro-computed tomography analysis of the human tuberculous lung reveals remarkable heterogeneity in three-dimensional granuloma morphology.  204:583. 2021

Racial segregation and respiratory outcomes among urban black residents with and at risk of chronic obstructive pulmonary disease.  204:536-545. 2021

Noninvasive oscillometry to measure pulmonary mechanics in preterm infants.  204:485-488. 2021

Pulmonary artery enlargement is associated with exacerbations and mortality in ever-smokers with preserved ratio impaired spirometry.  204:481-485. 2021

Update in chronic obstructive pulmonary disease 2020.  204:14-22. 2021

A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele.  203:1522-1532. 2021

Urban–Rural Disparities in Deaths from Chronic Lower Respiratory Disease in the United States.  203:769-772. 2021

Association between inhaled corticosteroids and expiratory central airway collapse in smokers.  203:518-521. 2021

Reply to Mezidi et al..  203:392-394. 2021

Computed tomography–based airway surface area–to-volume ratio for phenotyping airway remodeling in chronic obstructive pulmonary disease.  203:185-191. 2021

Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation.  203:54-66. 2021

Contribution of individual and neighborhood factors to racial disparities in respiratory outcomes.  203:987-997. 2021

Mucus plugs and emphysema in the pathophysiology of airflow obstruction and hypoxemia in smokers.  203:957-968. 2021

Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis.  200:1402-1413. 2021

Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR.  202:1271-1282. 2020

The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study a randomized, double-blind, multicenter clinical trial.  202:1237-1243. 2020

Reply to Suissa.  202:773-774. 2020

A fatal case of pneumocephalus during computed tomography-guided lung biopsy.  201:E83-E84. 2020

Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease.  201:1508-1516. 2020

Cystic fibrosis: Emergence of highly effective targeted therapeutics and potential clinical implications.  201:1193-1208. 2020

Reply to de Steenhuijsen Piters and Bogaert.  201:1311-1312. 2020

Predicting Pneumonia in Chronic Obstructive Pulmonary Disease Have We Unraveled the Network of Risks?.  201:1026-1027. 2020

Human Fetal Lungs Harbor a Microbiome Signature.  201:1002-1006. 2020

Disease progression modeling in chronic obstructive pulmonary disease.  201:294-302. 2020

Clinical development and research applications of the chronic obstructive pulmonary disease assessment test.  201:1058-1067. 2020

Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males.  201:996-998. 2020

Hyperoxia injury in the developing lung is mediated by mesenchymal expression of Wnt5A.  201:1249-1262. 2020

Reply to Gagnon et al..  201:120. 2020

Reply to moy.  200:1443-1444. 2019

Sugarcoating lung injury: A novel role for high-molecular-weight hyaluronan in pneumonia.  200:1197-1198. 2019

A genetic risk score associated with chronic obstructive pulmonary disease susceptibility and lung structure on computed tomography.  200:721-731. 2019

Arterial vascular pruning, right ventricular size, and clinical outcomes in chronic obstructive pulmonary disease a longitudinal observational study.  200:454-461. 2019

Chronic obstructive pulmonary disease in America's black population.  200:423-430. 2019

Video telehealth pulmonary rehabilitation intervention in chronic obstructive pulmonary disease reduces 30-day readmissions.  200:511-513. 2019

Update in pulmonary fibrosis 2018.  200:292-300. 2019

Exposure to greater air pollution when traveling abroad is associated with decreased lung function.  199:1570-1572. 2019

Update in chronic obstructive pulmonary disease 2018.  199:1462-1470. 2019

Imaging advances in chronic obstructive pulmonary disease insights from the genetic epidemiology of chronic obstructive pulmonary disease (COPDGene) study.  199:286-301. 2019

Life-course smoking trajectories and risk for emphysema in middle age: The CARDIA Lung study.  199:237-240. 2019

Reply to Eapen et al.: Dysfunctional immunity and microbial adhesion molecules in smoking-induced pneumonia.  199:251-252. 2019

Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies.  200:133-139. 2019

Patient registries in idiopathic pulmonary fibrosis.  200:160-167. 2019

Reply to Finotti et al..  199:1444-1445. 2019

Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis.  200:199-208. 2019

ADAM9: A damaging player in chronic obstructive pulmonary disease.  198:1465-1466. 2018

Nosocomial pneumonia elicits an endothelial proteinopathy: Evidence for a source of neurotoxic amyloids in critically ill patients.  198:1575-1578. 2018

Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study.  198:1397-1405. 2018

Macrophage Rac2 is required to reduce the severity of cigarette smoke-induced pneumonia.  198:1288-1301. 2018

A multicenter randomized controlled trial of Zephyr Endobronchial Valve treatment in heterogeneous emphysema (LIBERATE).  198:1151-1164. 2018

Ataluren, a new therapeutic for alpha-1 antitrypsin-deficient individuals with nonsense mutations.  198:1099-1102. 2018

Protein tyrosine phosphatase-N13 promotes myofibroblast resistance to apoptosis in idiopathic pulmonary fibrosis.  198:914-927. 2018

Maternal smoking induces acquired CFTR dysfunction in neonatal rats.  198:672-674. 2018

Reversing mechanoinductive DSP expression by CRISPR/dCas9–mediated epigenome editing.  198:599-609. 2018

Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): A clinical trial.  198:526-528. 2018

Defining impaired respiratory health a paradigm shift for pulmonary medicine.  198:440-446. 2018

Early chronic obstructive pulmonary disease or early detection of mild disease?.  198:411-412. 2018

Future research directions in pneumonia.  198:256-263. 2018

Things we “kNOw” and do not “kNOw” about pulmonary hypertension.  198:151-152. 2018

Exacerbations of chronic obstructive pulmonary disease and cardiac events a post hoc cohort analysis from the SUMMIT randomized clinical trial.  198:51-57. 2018

Control of breathing in preterm infants: Neonatal ICU and beyond.  197:1518-1520. 2018

Generic respiratory symptoms and branded lung diseases: Same Difference?.  197:1521-1523. 2018

HIV gp120 in the lungs of antiretroviral therapy-treated individuals impairs alveolar macrophage responses to pneumococci.  197:1604-1615. 2018

Respiratory symptoms in young adults and future lung disease the cardia lung study.  197:1616-1624. 2018

Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement.  197:1483-1486. 2018

Reply to shah et al..  197:1363-1364. 2018

Does extracorporeal membrane oxygenation improve survival in pediatric acute respiratory failure?.  197:1177-1186. 2018

Novel method for noninvasive sampling of the distal airspace in acute respiratory distress syndrome.  197:1027-1035. 2018

MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway Epithelia.  197:632-643. 2018

Randomized controlled trial of urokinase versus placebo for nondraining malignant pleural effusion.  197:502-508. 2018

Quantitative evidence for revising the definition of primary graft dysfunction after lung transplant.  197:235-243. 2018

Cardiac morphometry on computed tomography and exacerbation reduction with β-blocker therapy in chronic obstructive pulmonary disease.  196:1484-1488. 2017

Signs of gas trapping in normal lung density regions in smokers.  196:1404-1410. 2017

Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results.  196:1144-1151. 2017

Recovery from critical illness: Physical rehabilitation in the intensive care unit, timing of persistent critical illness, and caregiver outcomes.  196:1068-1070. 2017

Vascular endothelial mitochondrial function predicts death or pulmonary outcomes in preterm infants.  196:1040-1049. 2017

Computed tomography measure of lung at risk and lung function decline in chronic obstructive pulmonary disease.  196:569-576. 2017

Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling.  196:609-620. 2017

FEV1 decline in patients with chronic obstructive pulmonary disease: Reply.  195:1677. 2017

Pulmonary hypertension and precision medicine through the "omics" looking glass.  195:1558-1560. 2017

Reply: FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease..  195:1677. 2017

Association between cardiorespiratory fitness and lung health from young adulthood to middle ages.  195:1236-1243. 2017

Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction.  195:881-888. 2017

Sequelae of donor-derived mollicutes transmission in lung recipients.  195:687-689. 2017

Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease.  195:324-330. 2017

Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome: Insights from the LUNG SAFE Study.  195:67-77. 2017

What is in a pattern? that which we call idiopathic pulmonary fibrosis by any other pattern would behave alike!.  195:10-12. 2017

All about Asthma: Association with Obstructive Sleep Apnea, Management, and Overlap with Chronic Obstructive Pulmonary Disease.  194:1423-1425. 2016

National institute of environmental health sciences: 50 years of advancing science and improving lung health.  194:1190-1195. 2016

Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations.  194:1092-1103. 2016

Hidden in plain sight: Lung impairment in ischemic heart disease.  194:528-530. 2016

Reply.  194:522. 2016

Reply: It Is Too Early to Say No Place for High-Frequency Oscillatory Ventilation in Children with Respiratory Failure..  194:522. 2016

Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease.  194:178-184. 2016

Compartmentalization is key in limiting nitric oxide scavenging by cell-free hemoglobin.  193:1072-1074. 2016

Reply.  193:1068-1069. 2016

Reply: Do We Really Know How to Use High-Frequency Oscillatory Ventilation in Critically Ill Children?.  193:1068-1069. 2016

Oxidative modifications of protein tyrosyl residues are increased in plasma of human subjects with interstitial lung disease.  193:861-866. 2016

Early high-frequency oscillatory ventilation in pediatric acute respiratory failure: A propensity score analysis.  193:495-503. 2016

Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis.  192:1462-1474. 2015

Recovery of acquired cystic fibrosis transmembrane conductance regulator dysfunction after smoking cessation.  192:1521-1524. 2015

Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension.  192:1345-1354. 2015

A fragment in time: Elastin peptides and progression of emphysema.  192:1141-1143. 2015

Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age..  192:76-85. 2015

Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation.  191:455-463. 2015

Blue Journal Conference: Aging and susceptibility to lung disease.  191:261-269. 2015

A randomized, placebo-controlled trial of roflumilast effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease.  192:934-942. 2015

Cardiotoxicity during invasive pneumococcal disease.  191:739-745. 2015

Noninvasive computed tomography-based risk stratification of lung adenocarcinomas in the national lung screening trial.  192:737-744. 2015

Extracorporeal membrane oxygenation for acute respiratory failure in adults: The need for pulmonary INTERMACS.  190:1321-1322. 2014

Is pulmonary hypertension a metabolic disease?.  190:973-975. 2014

An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease.  190:51-61. 2014

Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation.  189:1564-1567. 2014

Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.  189:1503-1508. 2014

C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.  189:966-974. 2014

Reply.  189:869-870. 2014

Tertiary lymphoid structures target the antitumor immune response to lung cancer.  189:767-769. 2014

Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.  189:567-575. 2014

A functional anatomic defect of the cystic fibrosis airway.  190:421-432. 2014

A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation.  190:522-532. 2014

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.  190:175-184. 2014

Genome-wide association identifies regulatory loci associated with distinct local histogram emphysema patterns.  190:399-409. 2014

Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes.  190:445-455. 2014

Thromboendarterectomy for chronic thromboembolic pulmonary hypertension in hereditary hemorrhagic telangiectasia.  189:112-114. 2014

Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.  188:1407-1412. 2013

Sleep apnea is associated with subclinical myocardial injury in the community: The ARIC-SHHS study.  188:1460-1465. 2013

Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.  188:1321-1330. 2013

AECOPD: Acute exacerbations of chronic obstructive cardiopulmonary disease?.  188:1046-1048. 2013

S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis.  188:1137-1146. 2013

High-frequency oscillatory ventilation, microRNAs in pulmonary hypertension, and gastric residual volumes..  188:508-509. 2013

Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.  188:231-239. 2013

Cyclooxygenase-2 inhibits T helper cell type 9 differentiation during allergic lung inflammation via down-regulation of IL-17RB.  187:812-822. 2013

Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.  187:768-775. 2013

Clinical risk factors for primary graft dysfunction after lung transplantation.  187:527-534. 2013

A young hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: Is ivacaftor an option for therapy?.  186:694-696. 2012

Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction.  186:622-632. 2012

Altered DNA methylation profile in idiopathic pulmonary fibrosis.  186:525-535. 2012

Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.  186:546-552. 2012

Retinoic acid-related orphan receptor-α is induced in the setting of DNA damage and promotes pulmonary emphysema.  186:412-419. 2012

Modern age pathology of pulmonary arterial hypertension.  186:261-272. 2012

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.  186:88-95. 2012

Update in diffuse parenchymal lung disease 2011.  186:24-29. 2012

Computed axial tomography scans, calories, and computers.  185:584-585. 2012

Lung endothelial Ca ²⁺ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6.  185:160-170. 2012

Obesity and primary graft dysfunction after lung transplantation: The lung transplant outcomes group obesity study.  184:1055-1061. 2011

A Trojan horse strategy to deliver amikacin to mycobacterial granulomas [1].  184:860. 2011

The missing link between smoking and COPD autoreactivity?.  184:747-749. 2011

Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation.  184:37-49. 2011

Active and passive cigarette smoking and acute lung injury after severe blunt trauma.  183:1660-1665. 2011

Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants.  183:1715-1722. 2011

ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio.  183:1344-1353. 2011

Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort.  183:885-890. 2011

Recommended Reading from the University of Alabama Fellows: J. Allen Cooper, Program Director..  183:411-412. 2011

Targeted delivery of amikacin into granuloma.  182:1546-1553. 2010

Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils.  182:1516-1523. 2010

Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair.  182:1030-1037. 2010

Cystic fibrosis pulmonary guidelines: Pulmonary complications: Hemoptysis and pneumothorax.  182:298-306. 2010

Is there a doctor in the house? The downside of 24/7 attending coverage in academic intensive care units.  181:1280-1281. 2010

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.  181:604-610. 2010

Latent herpesvirus infection augments experimental pulmonary fibrosis.  181:465-477. 2010

Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease.  181:438-445. 2010

What is autoimmunity and why is it likely to be important in chronic lung disease?.  181:4-5. 2010

Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.  180:1010-1015. 2009

Deletion of Pten expands lung epithelial progenitor pools and confers resistance to airway injury.  180:701-712. 2009

Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.  180:499-505. 2009

Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.  180:468-474. 2009

Are telomere lengths of leukocytes from patients with pulmonary fibrosis really genetically determined?.  179:852. 2009

Bcl-2 suppresses sarcoplasmic/endoplasmic reticulum Ca21-ATPase expression in cystic fibrosis airways role in oxidant-mediated cell death.  179:816-826. 2009

Biologic lung volume reduction in advanced upper lobe emphysema phase 2 results.  179:791-798. 2009

Antiinflammatory effects of hydrogen peroxide in neutrophil activation and acute lung injury.  179:694-704. 2009

Regulation of Thy-1 Expression by Histone Modifications in Lung Fibroblast..  179. 2009

Potential role of high-mobility group box 1 in cystic fibrosis airway disease.  178:822-831. 2008

CD28 down-regulation on CD4 T cells is a marker for graft dysfunction in lung transplant recipients.  178:765-773. 2008

Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury.  178:168-179. 2008

Screening contacts of tuberculosis: Overcoming obstacles with an old tool.  177:939-940. 2008

Autoantibodies in patients with chronic obstructive pulmonary disease.  177:156-163. 2008

BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.  177:75-81. 2008

On treatment outcomes of patients with HIV and tuberculosis [1].  177:121. 2008

Ozone, a malady for all ages.  176:107-108. 2007

Importance of phosphoinositide 3-kinase γ in the host defense against pneumococcal infection.  175:958-966. 2007

One more prediction rule: Has anything new been added? [1].  175:743. 2007

Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.  175:69-74. 2007

Children's secondhand smoke exposure in African-American families 2007

Measurement of secondhand smoke exposure in children using a point of care urine dipstick assay for cotinine 2007

Modulatory role for retinoid-related orphan receptor α in allergen-induced lung inflammation.  174:1299-1309. 2006

Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: An NHLBI workshop report.  174:373-378. 2006

Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus.  173:673-682. 2006

Reactive species mediate inhibition of alveolar type II sodium transport during mycoplasma infection.  173:334-344. 2006

Bombesin-like peptides: Modulators of inflammation in acute lung injury?.  173:1-2. 2006

Reevaluating neonatal resuscitation with 100% oxygen.  172:1360-1361. 2005

The mysterious pulmonary brush cell: A cell in search of a function.  172:136-139. 2005

Oleic acid damages ion transport promotes alveolar edema: The dark side of healthy living.  171:424-425. 2005

Loss of bone density with inhaled triamcinoline in lung health study II.  170:1302-1309. 2004

Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys.  170:1153-1157. 2004

Asthma self-management, self-efficacy, and resilience in adolescents attending asthma camp 2004

Parent and child agreement on questionnaires for asthma case detection 2004

A Genome-Wide Scan of Pulmonary Function Measures in the National Heart, Lung, and Blood Institute Family Heart Study.  167:1528-1533. 2003

Statin use is associated with improved function and survival of lung allografts.  167:1271-1278. 2003

Nontuberculous mycobacteria: I: Multicenter prevalence study in cystic fibrosis.  167:828-834. 2003

Secondhand smoke exposure and school-age children 2003

A decision tree for tuberculosis contact investigation.  166:1122-1127. 2002

Fibrinolysis in the pleural space. Breaking the bonds that bind.  166:909-910. 2002

ATS statement: Guidelines for the six-minute walk test.  166:111-117. 2002

Oligoclonal CD4⁺ T cell expansions in lung transplant recipients with obliterative bronchiolitis.  165:1439-1444. 2002

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial.  165:800-804. 2002

Genetic loci influencing lung function: A genomewide scan in the Framingham Study.  165:795-799. 2002

Asthma education in elementary school children and teachers 2002

ETS avoidance behaviors 2002

Heritability of longitudinal change in lung function: The Framingham study.  164:1655-1659. 2001

Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.  164:193-196. 2001

Attenuation of interleukin 8-induced nasal inflammation by an inhibitor peptide.  163:1198-1205. 2001

Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.  163:1683-1692. 2001

Increased levels of nitrate and surfactant protein A nitration in the pulmonary edema fluid of patients with acute lung injury.  163:166-172. 2001

Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome.  163:503-510. 2001

Trends in asthma prevalence and morbidity in Head Start graduates 2001

Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.  163:1087-1092. 2001

Talc induces apoptosis in human malignant mesothelioma cells in vitro..  161:595-600. 2000

Asthma prevalence and morbidity in Head Start Graduates 2000

Cyclophosphamide prevents systemic keratinocyte growth factor-induced up-regulation of surfactant protein A after allogeneic transplant in mice.  162:1884-1890. 2000

DETANONOate, a nitric oxide donor, decreases amiloride-sensitive alveolar fluid clearance in rabbits.  161:1154-1160. 2000

Heterogeneous geographic distribution of inner city pediatric asthma admissions in Birmingham 2000

Management of malignant pleural effusions.  162:1987-2001. 2000

Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts.  161:2035-2042. 2000

Results of a school-based multi-stage screening procedure for asthma 2000

School environments and children with asthma 2000

Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: The lung health study.  161:381-390. 2000

Talc induces apoptosis in human malignant mesothelioma cells in vitro.  161:595-600. 2000

Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural mesothelial cells..  159:1653-1659. 1999

Acid-induced lung injury: Protective effect of anti-interleukin-8 pretreatment on alveolar epithelial barrier function in rabbits.  160:1450-1456. 1999

Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural mesothelial cells.  159:1653-1659. 1999

Identification of questions that best predict new diagnosis of asthma in children 1999

Interleukin-8 mediates injury from smoke inhalation to both the lung endothelial and the alveolar epithelial barriers in rabbits.  160:1443-1449. 1999

Leptin prevents respiratory depression in obesity.  159:1477-1484. 1999

Reporting of symptoms in childhood asthma: Parent and child comparisons 1999

Advances in prevention and education in lung disease.  157. 1998

Segregation analysis of pulmonary function among families in the framingham study.  157:1445-1451. 1998

Talc-induced expression of C-C and C-X-C chemokines and intercellular adhesion molecule-1 in mesothelial cells.  158:971-978. 1998

Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia: Role in acute lung injury.  158:299-305. 1998

Biological markers of acute lung injury: Prognostic and pathogenetic significance.  155:1187-1205. 1997

The epithelium as a target of glucocorticoid action in the treatment of asthma..  154:S16-S19. 1996

Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate ± amiloride in normal human adults.  154:217-223. 1996

Aerosolized cyclosporine in lung recipients with refractory chronic rejection.  153:1451-1455. 1996

Lung injury after hepatoenteric ischemia-reperfusion: Role of xanthine oxidase.  154:1364-1369. 1996

The epithelium as a target of glucocorticoid action in the treatment of asthma.  154. 1996

Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor.  153:1166-1168. 1996

Clinical risk factors for pulmonary barotrauma: A multivariate analysis.  152:1235-1240. 1995

Delivery and distribution of aerosolized cyclosporine in lung allograft recipients.  151:516-521. 1995

Hyperoxic lung injury reduces exogenous surfactant clearance in vivo.  151:1843-1847. 1995

Laboratory contamination of Mycobacterium tuberculosis cultures.  152:1702-1704. 1995

Resistance of the alveolar epithelium to injury from septic shock in sheep.  151:1093-1100. 1995

Development of pulmonary infection in mice inoculated with Blastomyces dermatitidis conidia..  149:500-509. 1994

Measures for use in asthma clinical research. Overview of the NIH workshop..  149:S1-S8. 1994

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.  150:146-152. 1994

Development of pulmonary infection in mice inoculated with Blastomyces dermatitidis conidia.  149:500-509. 1994

Load detection in subjects with sleep-induced upper airway obstruction.  149:727-730. 1994